Large Molecule Bioanalysis done differently

To help you achieve more.

BioAgilytix has evolved the model for partnership in large molecule bioanalysis to benefit our customers and the patients they serve.

Services Delivered Scientist to Scientist

Our fully integrated GxP services are driven by your assay requirements and delivered by our veteran scientists – collaboratively, accurately, and on time.

biomarkers

Biomarkers

immunogenicity

Immunogenicity

pharmacokinetics

Pharmacokinetics (PK)

cell-based-assays

Cell-Based Assays

Solutions Enabled by World-Leading Expertise

Our team is comprised of recognized experts in effectively navigating complex and evolving opportunities for biotherapeutics innovation.

biosimilars

Biosimilars

gene-therapy

Gene Therapy

antibody-drug-conjugates

Antibody Drug Conjugates (ADCs)

immuno-oncology

Immuno-oncology

The Bioagilytix Perspective

Explore the BioAgilytix way of thinking. Visit our Resource Center to learn more about our scientists’ expertise through case studies, blogs, industry articles and other scientific resources.

resource center

Visit Resource Center

usa europe labs

Advanced facilities to support all phases of large molecule global studies.

    LinkedIn Company Updates

  • 2 Days Agoview on linkedin

    BioAgilytix

    Glaucoma affects 70 million people worldwide, but the mechanisms that contribute to the disease aren’t yet fully understood. A recent study suggests that glaucoma could actually be an autoimmune disease. Learn more via Genetic Engineering & Biotechnology News: https://lnkd.in/g7Bn8AY

  • 2 Days Agoview on linkedin

    BioAgilytix

    Are you attending IDDST-2018? Join BioAgilytix’s Todd Lester today for his presentation entitled “Recommendations for the Development and Validation of Neutralizing Antibody Assays in Support of Biosimilar Assessment”. The session begins at 3:25pm in the Enterprise Room, 3rd Floor. Details here: https://lnkd.in/eGk5Nxv

  • 3 Days Agoview on linkedin

    BioAgilytix

    Introducing new bioanalytical technologies, or improvements to existing technology, in the middle of a project is inherently risky. How do you determine if it is worth the risk? We discuss with Bioanalysis Zone: https://lnkd.in/gyNAiWh